American Marconi Wireless News - Hypha Labs Expands List of Functional Mushrooms Able to be Produced in its Revolutionary Mushroom Accelerator

LAS VEGAS, NV / ACCESS Newswire / August 11, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), an A.I. powered pioneer in functional mushroom sciences and the creator of the MicroPearls™ suite of products, is pleased to announce that the Company has expanded the array of functional mushroom ingredients that can be harvested at home in an eight day cycle using the most recent enhancements of its revolutionary device.

Recent breakthroughs in the Company's R&D efforts now allow for the most potent HOME production of the active ingredients of most of the world's most popular mushroom ingredients including the following:

Reishi (Ganoderma lucidum)

• Traditionally valued for promoting a sense of calm and inner balance

• Often used in wellness routines focused on relaxation and stress support

• Associated with long-standing practices aimed at enhancing vitality and longevity

• Commonly included in evening or wind-down supplements

• Contains naturally occurring compounds like triterpenes and polysaccharides

• Frequently chosen for holistic wellness and lifestyle support

Lion's Mane (Hericium erinaceus)

• Traditionally used to support mental clarity and focus

• Popular in wellness circles for its role in cognitive wellness routines

• Often featured in daily blends aimed at creativity and productivity

• A go-to ingredient in nootropic and brain health stacks

• Contains naturally occurring compounds like hericenones and erinacines

• Embraced in functional wellness for its link to clarity and mood balance

Cordyceps (Cordyceps militaris / sinensis)

• Traditionally linked to stamina and endurance in ancient wellness systems

• Often used in routines that support natural energy and performance

• Commonly featured in pre-workout or vitality-enhancing blends

• Valued for its association with physical resilience and recovery

• Contains bioactive compounds such as cordycepin and adenosine

• A favorite among those seeking sustained wellness and drive

"Simply put, Hypha Lab's Mushroom Accelerator is changing the game. It's not just another kitchen gadget-it's a breakthrough. This machine creates the most potent, fresh, and high-quality medicinal mushroom ingredients on Earth," stated Stone Douglass, CEO, Hypha Labs.

"Nothing compares to the freshness and potency of what comes straight from our device. Traditional mushroom powders and capsules? They're yesterday's solution-dried, diluted, and far from their peak. MicroPearls are made fresh on demand, delivering maximum impact exactly when you need it."

About Hypha Labs, Inc.

The company has developed revolutionary, cutting-edge technology focused on new methods of producing the active ingredients found in a wide array of functional mushrooms using its patent-pending mushroom accelerators. The Company is positioning itself to play an important role in the burgeoning Functional Mushroom industry in addition to being a disruptive force in future and emerging mushroom opportunities. Visit us at HyphaLabs.com.

SAFE HARBOR FORWARD LOOKING STATEMENTS:

This press release may contain forward looking statements that are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues related to our financial performance, expected revenue, contracts, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC) and on the OTC Disclosure & News Service (OTCDNS). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC and/or OTCDNS. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to the risk that we will not be able to find and secure construction contracts and the necessary assets that will enable us to become profitable. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC and/or OTCDNS filings. We have incurred and will continue to incur significant expenses in our development stage, noting that there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. New lines of business in the construction industry may expose us to additional legal and regulatory costs and unknown exposure(s), the impact of which cannot be predicted at this time. Words such as "estimate," "project," "predict," "will," "would," "should," "could," "may," "might," "anticipate," "plan," "intend," "believe," "expect," "aim," "goal," "target," "objective," "likely" or similar expressions that convey the prospective nature of events or outcomes generally indicate forward-looking statements. You should not place undue reliance on these forward-looking statements, which speak only as of this press release. Unless legally required, we undertake no obligation to update, modify or withdraw any forward-looking statements, because of new information, future events or otherwise.

From time to time, the Company may post new and material information on its website or through its social media profiles at the links below:

LN: https://www.linkedin.com/company/hypha-labs-inc/
FB: https://www.facebook.com/hyphalabs
IG: https://www.instagram.com/hyphalabsinc/
Twitter: https://x.com/Hypha_Labs

For more information about Hypha Labs visit HyphaLabs.com

For the Company's current Investor Presentation please visit www.HyphaLabs.com/deck

Investor and Media Relations:
Integrity Media Inc.
(888) 216-3595
[email protected]

SOURCE: Hypha Labs, Inc.

View the original press release on ACCESS Newswire

J.Williams--AMWN